Phase II Study of Pazopanib Maintenance for SCLC
Phase 2
20 Years
N/A
20 Years
N/A
Not Enrolling
Both
SCLC
Both
SCLC
Trial Information
Phase II Study of Pazopanib Maintenance for SCLC
Inclusion Criteria:
- histologically confirmed SCLC
- no disease progression after 6 cycles of etoposide/platinum 1st-line therapy
- history of 6 cycles of etoposide/platinum 1st-line therapy
- between 21 days and 42 days since C6D1 of etoposide/platinum
- no symptomatic brain meta
Exclusion Criteria:
- poor hepatic, renal function
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Outcome Measure:
Progression-free survival
Outcome Time Frame:
12 months
Safety Issue:
No
Authority:
Korea: Food and Drug Administration
Study ID:
2012-09-060-002
NCT ID:
NCT01797874
Start Date:
March 2013
Completion Date:
Related Keywords:
- SCLC
- pazopanib maintenance
- efficacy
- Small Cell Lung Carcinoma
Name | Location |
|---|
